CTOs on the Move

Pharmacy Examining Board of Canada

www.pebe.ca

 
Pharmacy Examining Board of Canada is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.pebe.ca
  • 717 Church St
    Toronto, ON CAN M4W 2M4
  • Phone: 416.979.2431

Executives

Name Title Contact Details

Similar Companies

Cobalt Pharmaceuticals

Cobalt Pharmaceuticals Inc. is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Deltanoid Pharmaceuticals

Deltanoid Pharmaceuticals, Inc. is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IM Cannabis

IM Cannabis (IMC) is one of the world`s pioneering medical-grade cannabis companies, with operations in Israel, across Europe, and Canada. Over the past decade, IMC has established its premium medical cannabis brand, comprising a full spectrum of products known for their quality, consistency, and purity, such as ROMA, TEL AVIV and LONDON. In Europe, IMC has established a fully operational, vertically integrated medical cannabis business, spearheaded by its EU-GMP certified distribution arm in Germany and augmented by strategic alliances with certified pan-EUGMP certified suppliers. To this end, IMC has formed strong strategic alliances within the international medical cannabis industry, aiming for a dominant position in satisfying the global demand for high-quality medical cannabis products, which both physicians and patients can rely upon. IMC further intends to leverage its expertise in Israel in order to bolster its research and development initiative while collaborating with world-renowned scientists on cutting-edge technology for the benefit of patients around the world

La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia

Virtus Pharmaceuticals

Virtus Pharmaceuticals’ mission is to be the leading specialty niche pharmaceutical company providing the highest quality products through experienced leadership, innovative approaches and outstanding customer service.